|View printer-friendly version|
|Quidel Announces Over-The-Counter Flu Test in European Countries|
SAN DIEGO, Dec. 19 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today that it has launched its rapid QuickVue(R) Influenza Test "over-the-counter" to consumers in three European countries. This test is now available in pharmacies in Italy, Germany and the United Kingdom. The over-the-counter QuickVue Influenza Test detects influenza types A and B within 10 minutes using a simple nasal swab. The test allows the consumer the convenience of testing at home to quickly rule in or rule out the flu and provides the opportunity for prompt and proper treatment by a healthcare professional.
Tens of millions of people worldwide contract influenza each year. Influenza is a highly contagious, acute viral infection of the upper respiratory tract. The virus can be dangerous and even deadly, particularly in high-risk patients and patients with underlying respiratory disease. In addition, flu-like symptoms can be indicative of other illnesses including some that are potentially dangerous.
Recently, the U.S. Food and Drug Administration (FDA) granted CLIA waiver for Quidel's QuickVue Influenza Test in the U.S. providing an estimated 100,000 U.S. physicians' office laboratories access to this test.
Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction.
This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.